{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T06:02:31Z","timestamp":1779688951364,"version":"3.53.1"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Suzhou City Applied Basic Research (Medical and Health) Technology Innovation Project","award":["SYW2024028"],"award-info":[{"award-number":["SYW2024028"]}]},{"name":"Suzhou City Applied Basic Research (Medical and Health) Technology Innovation Project","award":["SKY2022192"],"award-info":[{"award-number":["SKY2022192"]}]},{"name":"Suzhou Clinical Medical Center Construction Project","award":["Szlcyxzxj202107"],"award-info":[{"award-number":["Szlcyxzxj202107"]}]},{"name":"Suzhou City \"Science and Education Promoting Health\" Youth Science and Technology Project","award":["KJXW2023040"],"award-info":[{"award-number":["KJXW2023040"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s10620-025-09546-2","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T13:19:35Z","timestamp":1763990375000},"page":"1873-1888","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Prognostic and Immunological Significance of TIPARP in Pancreatic Cancer"],"prefix":"10.1007","volume":"71","author":[{"given":"Hanlin","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqiao","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujia","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongying","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwu","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiming","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinwei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lining","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"9546_CR1","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1016\/s0140-6736(25)00261-2","volume":"10485","author":"TF Stoop","year":"2025","unstructured":"Stoop TF, Javed AA, Oba A, Koerkamp BG, Seufferlein T, Wilmink JW et al. Pancreatic cancer. Lancet (London, England) 2025;10485:1182\u20131202. https:\/\/doi.org\/10.1016\/s0140-6736(25)00261-2.","journal-title":"Lancet (London, England)"},{"key":"9546_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2021.06.027","author":"J Cai","year":"2021","unstructured":"Cai J, Chen HD, Lu M, Zhang YH, Lu B, You L et al. Advances in the epidemiology of pancreatic cancer: trends, risk factors, screening, and prognosis. Cancer Lett. 2021. https:\/\/doi.org\/10.1016\/j.canlet.2021.06.027.","journal-title":"Cancer Lett"},{"key":"9546_CR3","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1136\/gutjnl-2021-326311","volume":"8","author":"CJ Cabasag","year":"2021","unstructured":"Cabasag CJ, Ferlay J, Laversanne M, Vignat J, Weber A, Soerjomataram I et al. Pancreatic cancer: an increasing global public health concern. Gut 2021;8:1686\u20131687. https:\/\/doi.org\/10.1136\/gutjnl-2021-326311.","journal-title":"Gut"},{"key":"9546_CR4","doi-asserted-by":"publisher","first-page":"241","DOI":"10.3322\/canjclin.50.4.241","volume":"4","author":"KD Lillemoe","year":"2000","unstructured":"Lillemoe KD, Yeo CJ, Cameron JL. Pancreatic cancer: State-of-the-art care. Ca-Cancer J Clin 2000;4:241\u2013268. https:\/\/doi.org\/10.3322\/canjclin.50.4.241.","journal-title":"Ca-Cancer J Clin"},{"key":"9546_CR5","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1023\/A:1008382029375","volume":"10","author":"EP DiMagno","year":"1999","unstructured":"DiMagno EP. Pancreatic cancer: clinical presentation, pitfalls and early clues. Ann Oncol Off J Eur Soc Med Oncol 1999;10:140\u2013142. https:\/\/doi.org\/10.1023\/A:1008382029375.","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"9546_CR6","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S2468-1253(16)30213-8","volume":"2","author":"G The Lancet","year":"2017","unstructured":"The Lancet G, Hepatology,. Pancreatic cancer: how can we tackle the lack of progress? lancet Gastroenterol Hepatol 2017;2:73. https:\/\/doi.org\/10.1016\/S2468-1253(16)30213-8.","journal-title":"lancet Gastroenterol Hepatol"},{"key":"9546_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/Nchembio.2568","volume":"3","author":"MS Cohen","year":"2018","unstructured":"Cohen MS, Chang P. Insights into the biogenesis, function, and regulation of ADP-ribosylation. Nature Chem Biol 2018;3:236\u2013243. https:\/\/doi.org\/10.1038\/Nchembio.2568.","journal-title":"Nature Chem Biol"},{"key":"9546_CR8","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/j.ccell.2021.06.018","volume":"9","author":"JM Gozgit","year":"2021","unstructured":"Gozgit JM, Vasbinder MM, Abo RP, Kunii K, Kuplast-Barr KG, Gui B et al. PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity. Cancer Cell 2021;9:1214\u20131226. https:\/\/doi.org\/10.1016\/j.ccell.2021.06.018.","journal-title":"Cancer Cell"},{"key":"9546_CR9","doi-asserted-by":"publisher","first-page":"7532","DOI":"10.1021\/acs.jmedchem.2c00281","volume":"11","author":"MG Nizi","year":"2022","unstructured":"Nizi MG, Maksimainen MM, Lehti\u00f6 L, Tabarrini O. medicinal chemistry perspective on targeting mono-ADP-Ribosylating PARPs with small molecules. J Med Chem 2022;11:7532\u20137560. https:\/\/doi.org\/10.1021\/acs.jmedchem.2c00281.","journal-title":"J Med Chem"},{"key":"9546_CR10","doi-asserted-by":"publisher","first-page":"1604","DOI":"10.1093\/nar\/gks1337","volume":"3","author":"L MacPherson","year":"2013","unstructured":"MacPherson L, Tamblyn L, Rajendra S, Bralha F, McPherson JP, Matthews J. 2,3,7,8-Tetrachlorodibenzo\u2013dioxin poly(ADP-ribose) polymerase (TiPARP, ARTD14) is a mono-ADP-ribosyltransferase and repressor of aryl hydrocarbon receptor transactivation. Nucleic Acids Res 2013;3:1604\u20131621. https:\/\/doi.org\/10.1093\/nar\/gks1337.","journal-title":"Nucleic Acids Res"},{"key":"9546_CR11","doi-asserted-by":"publisher","first-page":"e2309047120","DOI":"10.1073\/pnas.2309047120","volume":"49","author":"P Manetsch","year":"2023","unstructured":"Manetsch P, B\u00f6hi F, Nowak K, Pedrioli DML, Hottiger MO. PARP7-mediated ADP- ribosylation of FRA1 promotes cancer cell growth by repressing IRF1-and IRF3-dependent apoptosis. Proc Natl Acad Sci USA 2023;49:e2309047120. https:\/\/doi.org\/10.1073\/pnas.2309047120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9546_CR12","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/s41588-025-02090-9","volume":"2","author":"SH Fong","year":"2025","unstructured":"Fong SH, Kuenzi BM, Mattson NM, Lee JH, Sanchez K, Bojorquez-Gomez A et al. A multilineage screen identifies actionable synthetic lethal interactions in human cancers. Nat Genet 2025;2:480\u2013480. https:\/\/doi.org\/10.1038\/s41588-025-02090-9.","journal-title":"Nat Genet"},{"key":"9546_CR13","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3390\/cells10030623","volume":"10","author":"M Rasmussen","year":"2021","unstructured":"Rasmussen M, Tan S, Somisetty VS, Hutin D, Olafsen NE, Moen A et al. PARP7 and mono-ADP-Ribosylation negatively regulate estrogen receptor \u03b1 signaling in human breast cancer cells. Cells 2021;10:623. https:\/\/doi.org\/10.3390\/cells10030623.","journal-title":"Cells"},{"key":"9546_CR14","doi-asserted-by":"publisher","first-page":"eabm4949","DOI":"10.1126\/scisignal.abm4949","volume":"702","author":"LK Ferrarelli","year":"2021","unstructured":"Ferrarelli LK. Uncloaking tumors. Sci Signal 2021;702:eabm4949. https:\/\/doi.org\/10.1126\/scisignal.abm4949.","journal-title":"Sci Signal"},{"key":"9546_CR15","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.cgh.2009.07.035","volume":"11","author":"T Furukawa","year":"2009","unstructured":"Furukawa T. Molecular pathology of pancreatic cancer: implications for molecular targeting therapy. Clin Gastroenterol Hepatol Off Clin Pract J Ame Gastroenterol Assoc 2009;11:S35\u2013S39. https:\/\/doi.org\/10.1016\/j.cgh.2009.07.035.","journal-title":"Clin Gastroenterol Hepatol Off Clin Pract J Ame Gastroenterol Assoc"},{"key":"9546_CR16","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1146\/annurev.genom.4.070802.110341","volume":"4","author":"DE Hansel","year":"2003","unstructured":"Hansel DE, Kern SE, Hruban RH. Molecular pathogenesis of pancreatic cancer. Ann Rev Genom Human Genet 2003;4:237\u2013256. https:\/\/doi.org\/10.1146\/annurev.genom.4.070802.110341.","journal-title":"Ann Rev Genom Human Genet"},{"key":"9546_CR17","doi-asserted-by":"publisher","first-page":"101368","DOI":"10.1016\/j.mam.2025.101368","volume":"103","author":"JY Zhang","year":"2025","unstructured":"Zhang JY, Kong XQ, Zhou BY, Li R, Yu ZA, Zhu JR et al. Metabolic reprogramming of drug resistance in pancreatic cancer: mechanisms and effects. Mol Asp Med 2025;103:101368. https:\/\/doi.org\/10.1016\/j.mam.2025.101368.","journal-title":"Mol Asp Med"},{"key":"9546_CR18","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.critrevonc.2017.03.026","volume":"114","author":"C Grasso","year":"2017","unstructured":"Grasso C, Jansen G, Giovannetti E. Drug resistance in pancreatic cancer: impact of altered energy metabolism. Crit Rev Oncol Hematol 2017;114:139\u2013152. https:\/\/doi.org\/10.1016\/j.critrevonc.2017.03.026.","journal-title":"Crit Rev Oncol Hematol"},{"key":"9546_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41575-022-00728-1","volume":"2","author":"CA Iacobuzio-Donahue","year":"2022","unstructured":"Iacobuzio-Donahue CA. The war on pancreatic cancer: progress and promise. Nat Rev Gastroenterol Hepatol 2022;2:75\u201376. https:\/\/doi.org\/10.1038\/s41575-022-00728-1.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"9546_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrc1630","volume":"6","author":"D Laheru","year":"2005","unstructured":"Laheru D, Jaffee EM. Immunotherapy for pancreatic cancer - Science driving clinical progress. Nature Rev Cancer 2005;6:459\u2013467. https:\/\/doi.org\/10.1038\/nrc1630.","journal-title":"Nature Rev Cancer"},{"key":"9546_CR21","doi-asserted-by":"publisher","first-page":"1513595","DOI":"10.3389\/fimmu.2024.1513595","volume":"15","author":"V Kannen","year":"2024","unstructured":"Kannen V, Rasmussen M, Das S, Giuliana P, Izzati FN, Choksi H et al. Loss of Parp7 increases type I interferon signalling and reduces pancreatic tumour growth by enhancing immune cell infiltration. Front Immunol 2024;15:1513595. https:\/\/doi.org\/10.3389\/fimmu.2024.1513595.","journal-title":"Front Immunol"},{"key":"9546_CR22","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.cell.2018.03.042","volume":"2","author":"C Hutter","year":"2018","unstructured":"Hutter C, Zenklusen JC. The cancer genome atlas: creating lasting value beyond its data. Cell 2018;2:283\u2013285. https:\/\/doi.org\/10.1016\/j.cell.2018.03.042.","journal-title":"Cell"},{"key":"9546_CR23","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1016\/j.cell.2018.03.059","volume":"2","author":"A Blum","year":"2018","unstructured":"Blum A, Wang PG, Zenklusen JC. SnapShot: TCGA-Analyzed Tumors. Cell 2018;2:530\u2013530. https:\/\/doi.org\/10.1016\/j.cell.2018.03.059.","journal-title":"Cell"},{"key":"9546_CR24","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1016\/j.jcmg.2024.06.004","volume":"11","author":"OM Abdelfattah","year":"2024","unstructured":"Abdelfattah OM, Jacquemyn X, Aglan A, Rowin E, Maron M, Martinez MW. Clinical outcomes in hypertrophic cardiomyopathy and no late gadolinium enhancement. JACC Cardiovasc Imaging 2024;11:1387\u20131388. https:\/\/doi.org\/10.1016\/j.jcmg.2024.06.004.","journal-title":"JACC Cardiovasc Imaging"},{"key":"9546_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1026331","author":"JY Tao","year":"2022","unstructured":"Tao JY, Li X, Liang CZ, Liu Y, Zhou J. Expression of basement membrane genes and their prognostic significance in clear cell renal cell carcinoma patients. Front Oncol. 2022. https:\/\/doi.org\/10.3389\/fonc.2022.1026331.","journal-title":"Front Oncol"},{"key":"9546_CR26","doi-asserted-by":"publisher","first-page":"W509","DOI":"10.1093\/nar\/gkaa407","volume":"W1","author":"TW Li","year":"2020","unstructured":"Li TW, Fu JX, Zeng ZX, Cohen D, Li J, Chen QM et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res 2020;W1:W509\u2013W514. https:\/\/doi.org\/10.1093\/nar\/gkaa407.","journal-title":"Nucleic Acids Res"},{"key":"9546_CR27","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1002\/jrsm.1346","volume":"4","author":"J Bowden","year":"2019","unstructured":"Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: a review. Res Synth Methods 2019;4:486\u2013496. https:\/\/doi.org\/10.1002\/jrsm.1346.","journal-title":"Res Synth Methods"},{"key":"9546_CR28","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10654-017-0255-x","volume":"5","author":"S Burgess","year":"2017","unstructured":"Burgess S, Thompson SG. Interpreting findings from Mendelian randomization using the MR-Egger method. Eur J Epidemiol 2017;5:377\u2013389. https:\/\/doi.org\/10.1007\/s10654-017-0255-x.","journal-title":"Eur J Epidemiol"},{"key":"9546_CR29","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/ije\/dyx034","volume":"6","author":"OO Yavorska","year":"2017","unstructured":"Yavorska OO, Burgess S. MendelianRandomization: an R package for performing Mendelian randomization analyses using summarized data. Int J Epidemiol 2017;6:1734\u20131739. https:\/\/doi.org\/10.1093\/ije\/dyx034.","journal-title":"Int J Epidemiol"},{"key":"9546_CR30","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s10495-023-01880-y","volume":"1\u20132","author":"W Zhu","year":"2023","unstructured":"Zhu W, Chen Z, Fu M, Li Q, Chen X, Li X et al. Cuprotosis clusters predict prognosis and immunotherapy response in low-grade glioma. Apoptosis Int J Program Cell Death 2023;1\u20132:169\u2013190. https:\/\/doi.org\/10.1007\/s10495-023-01880-y.","journal-title":"Apoptosis Int J Program Cell Death"},{"key":"9546_CR31","doi-asserted-by":"publisher","first-page":"3292","DOI":"10.1038\/s41596-024-01020-z","volume":"11","author":"SB Xu","year":"2024","unstructured":"Xu SB, Hu ER, Cai YT, Xie ZJ, Luo X, Zhan L et al. Using clusterProfiler to characterize multiomics data. Nat Protocols 2024;11:3292\u20133320. https:\/\/doi.org\/10.1038\/s41596-024-01020-z.","journal-title":"Nat Protocols"},{"key":"9546_CR32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","volume":"3","author":"E Sahai","year":"2020","unstructured":"Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, Evans RM et al. A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev. Cancer 2020;3:174\u2013186. https:\/\/doi.org\/10.1038\/s41568-019-0238-1.","journal-title":"Nat Rev. Cancer"},{"key":"9546_CR33","doi-asserted-by":"publisher","first-page":"10848","DOI":"10.1021\/acs.jmedchem.4c00296","volume":"13","author":"Y Gao","year":"2024","unstructured":"Gao Y, Duan JL, Wang CC, Yuan YH, Zhang PP, Wang ZH et al. Novel bifunctional conjugates targeting PD-L1\/PARP7 as dual immunotherapy for potential cancer treatment. J Med Chem 2024;13:10848\u201310874. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c00296.","journal-title":"J Med Chem"},{"key":"9546_CR34","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1038\/s44321-025-00214-6","volume":"5","author":"K Popova","year":"2025","unstructured":"Popova K, Benedum J, Engl M, L\u00fctgendorf-Caucig C, Fossati P, Widder J et al. PARP7 as a new target for activating anti-tumor immunity in cancer. EMBO Mol Med 2025;5:872\u2013888. https:\/\/doi.org\/10.1038\/s44321-025-00214-6.","journal-title":"EMBO Mol Med"},{"key":"9546_CR35","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2424985122","volume":"24","author":"A Gorelik","year":"2025","unstructured":"Gorelik A, Paulo JA, Schroeter CB, Lad M, Shurr A, Mastrokalou C et al. CRISPR screens and quantitative proteomics reveal remodeling of the aryl hydrocarbon receptor-driven proteome through PARP7 activity. Proc Natl Acad Sci USA 2025;24:e2424985122. https:\/\/doi.org\/10.1073\/pnas.2424985122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"9546_CR36","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","volume":"1","author":"Y He","year":"2021","unstructured":"He Y, Sun MM, Zhang GG, Yang J, Chen KS, Xu WW et al. Targeting PI3K\/Akt signal transduction for cancer therapy. Signal Transduct Targeted Ther 2021;1:425. https:\/\/doi.org\/10.1038\/s41392-021-00828-5.","journal-title":"Signal Transduct Targeted Ther"},{"key":"9546_CR37","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/0092-8674(87)90009-2","volume":"1","author":"AS Menko","year":"1987","unstructured":"Menko AS, Boettiger D. Occupation of the extracellular matrix receptor, integrin, is a control point for myogenic differentiation. Cell 1987;1:51\u201357. https:\/\/doi.org\/10.1016\/0092-8674(87)90009-2.","journal-title":"Cell"},{"key":"9546_CR38","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.molmed.2008.02.003","volume":"4","author":"J Y\u00e9lamos","year":"2008","unstructured":"Y\u00e9lamos J, Schreiber V, Dantzer F. Toward specific functions of poly(ADP-ribose) polymerase-2. Trends Mol Med 2008;4:169\u2013178. https:\/\/doi.org\/10.1016\/j.molmed.2008.02.003.","journal-title":"Trends Mol Med"},{"key":"9546_CR39","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1038\/s41423-024-01182-6","volume":"11","author":"F Naulin","year":"2024","unstructured":"Naulin F, Guilbaud E, Galluzzi L. PARP7 and nucleic acid-driven oncosuppression. Cell Mol Immunol 2024;11:1177\u20131179. https:\/\/doi.org\/10.1038\/s41423-024-01182-6.","journal-title":"Cell Mol Immunol"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09546-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-09546-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-09546-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T05:06:25Z","timestamp":1779685585000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-09546-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["9546"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-09546-2","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"20 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}